Ma Yifu

Showing 1 - 9 results of 9 for search 'Yifu Ma', query time: 0.04s
Refine Results
-
1
Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers by Yuehong Kong, Yuehong Kong, Yuehong Kong, Yifu Ma, Yifu Ma, Yifu Ma, Xiangrong Zhao, Xiangrong Zhao, Xiangrong Zhao, Jie Pan, Zhi Xu, Liyuan Zhang, Liyuan Zhang, Liyuan Zhang
Published 2021-03-01
Article -
2
PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report by Hong Xu, Hong Xu, Zhihui Hong, Meiling Xu, Meiling Xu, Meiling Xu, Yuehong Kong, Yuehong Kong, Yuehong Kong, Yifu Ma, Yifu Ma, Yifu Ma, Chanchan Shan, Pengfei Xing, Pengfei Xing, Pengfei Xing, Liyuan Zhang, Liyuan Zhang, Liyuan Zhang
Published 2022-07-01
Article -
3
The prognostic value of the lymph node ratio for local advanced gastric cancer patients with intensity-modulated radiation therapy and concurrent chemotherapy after radical gastrec... by Yongqiang Yang, Yifu Ma, Xiaoyong Xiang, Pengfei Xing, Yongyou Wu, Liyuan Zhang, Ye Tian
Published 2020-10-01
Article -
4
-
5
Cystine deprivation triggers CD36-mediated ferroptosis and dysfunction of tumor infiltrating CD8+ T cells by Chenfeng Han, Minmin Ge, Pengfei Xing, Tian Xia, Cangang Zhang, Kaili Ma, Yifu Ma, Shicheng Li, Wenhui Li, Xiaowei Liu, Baojun Zhang, Liyuan Zhang, Lianjun Zhang
Published 2024-02-01
Article -
6
Deep brain stimulation combined with morroniside promotes neural plasticity and motor functional recovery after ischemic stroke by Yanxi Chen, Yanxi Chen, Zhidong Xu, Yifu Ma, Tingting Liu, Xin Tian, Zixin Zhu, Wenrong Zheng, Yufeng Wang, Ruifang Zheng, Jianguo Xing, Wen Wang, Fangling Sun
Published 2024-12-01
Article -
7
Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre s... by Yong Peng, Hong Zhang, Junjun Zhang, Liyuan Zhang, Pengfei Xing, Yuehong Kong, Rongzheng Chen, Meiling Xu, Guangqiang Chen, Zhihui Hong, Xiaoxiao Dai, Yifu Ma, Xiangrong Zhao, Chenyang Zhang
Published 2024-03-01
Article -
8
PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study by Yuehong Kong, Yuehong Kong, Yuehong Kong, Xiangrong Zhao, Xiangrong Zhao, Xiangrong Zhao, Meiling Xu, Meiling Xu, Meiling Xu, Jie Pan, Yifu Ma, Yifu Ma, Yifu Ma, Li Zou, Li Zou, Li Zou, Qiliang Peng, Qiliang Peng, Qiliang Peng, Junjun Zhang, Junjun Zhang, Junjun Zhang, Cunjin Su, Zhi Xu, Wei Zhou, Wei Zhou, Wei Zhou, Yong Peng, Yong Peng, Yong Peng, Jiabao Yang, Jiabao Yang, Jiabao Yang, Chengliang Zhou, Chengliang Zhou, Chengliang Zhou, Yujia Li, Yujia Li, Yujia Li, Qiuchen Guo, Guangqiang Chen, Hongya Wu, Hongya Wu, Pengfei Xing, Pengfei Xing, Pengfei Xing, Liyuan Zhang, Liyuan Zhang, Liyuan Zhang
Published 2022-07-01
Article -
9
Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study) by Yingying Xu MS, Yuehong Kong MS, Yifu Ma MS, Meiling Xu MS, Jiabao Yang MS, Junjun Zhang PhD, Rongzheng Chen MS, Guangqiang Chen MS, Zhihui Hong MS, Xiangrong Zhao MS, Chenyang Zhang MS, Pengfei Xing MS, Liyuan Zhang MD, Peifeng Zhao MS
Published 2024-06-01
Article